We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance
News

NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance

NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance
News

NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The ever increasing complexity and expense of drug discovery requires an excellent understanding of molecular targets and mechanism of action in disease early in the research phase to match high quality compound optimisation. Dualsystems offers a proprietary suite of technologies for drug and target profiling from a client’s phenotypic assays. Based on its advanced platforms to discover protein interactions, mechanism of action and target network, information is generated at an early stage of hit-to-lead, lead optimisation or candidate selection. These skills are complemented by the synthetic and medicinal chemistry expertise, the ADMET & DMPK and early toxicology services that NiKem has been providing to its clients over the last 10 years. The combined skills that Dualsystems and NiKem can now offer via a single point of contact make for a highly efficient drug discovery engine. All generated intellectual property is assigned to the client.

Dualsystems’ and NiKem’s combined technologies will help clients speed up their drug development by providing real-time information about drug candidates, their targets, their mechanisms of action and allow for a seamless downstream development of the molecules of interest.

Advertisement